ALLIANCEBERNSTEIN L.P. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$1,704,382
+42.0%
275,790
+16.8%
0.00%
Q1 2024$1,199,998
-15.2%
236,2200.0%0.00%
-100.0%
Q4 2023$1,414,958
-81.6%
236,220
-78.3%
0.00%
-66.7%
Q3 2023$7,693,666
+362.6%
1,086,676
+360.0%
0.00%
+200.0%
Q2 2023$1,662,989
-15.6%
236,2200.0%0.00%0.0%
Q1 2023$1,970,075
-27.4%
236,2200.0%0.00%0.0%
Q4 2022$2,711,806
-8.7%
236,220
+0.2%
0.00%0.0%
Q3 2022$2,970,000
+19.1%
235,7200.0%0.00%0.0%
Q2 2022$2,494,000
-24.3%
235,720
+16.3%
0.00%0.0%
Q1 2022$3,295,000
+1.7%
202,620
-13.4%
0.00%0.0%
Q4 2021$3,240,000
-3.6%
233,9200.0%0.00%0.0%
Q3 2021$3,361,000
-10.4%
233,920
-1.4%
0.00%
-50.0%
Q2 2021$3,752,000
+81.5%
237,320
+16.8%
0.00%
+100.0%
Q1 2021$2,067,000
+55.2%
203,220
+13.6%
0.00%0.0%
Q4 2020$1,332,000
+116.9%
178,8200.0%0.00%
Q3 2020$614,000
-31.7%
178,820
-5.2%
0.00%
-100.0%
Q2 2020$899,000
+86.1%
188,720
-21.8%
0.00%
Q1 2020$483,000
-8.9%
241,320
+57.0%
0.00%
Q4 2019$530,000
+20.5%
153,7200.0%0.00%
Q3 2019$440,000
-17.6%
153,720
+9.0%
0.00%
Q2 2019$534,000
-43.6%
141,020
+21.2%
0.00%
-100.0%
Q1 2019$947,000
+0.9%
116,3200.0%0.00%0.0%
Q4 2018$939,000
+5.7%
116,3200.0%0.00%0.0%
Q3 2018$888,000
+33.1%
116,3200.0%0.00%
Q2 2018$667,000
+20.2%
116,3200.0%0.00%
Q1 2018$555,000
+13.7%
116,320
+17.0%
0.00%
Q4 2017$488,000
-6.3%
99,4200.0%0.00%
Q3 2017$521,000
-12.9%
99,420
-7.6%
0.00%
Q2 2017$598,000
-33.8%
107,6200.0%0.00%
-100.0%
Q1 2017$904,000
+18.8%
107,620
-10.5%
0.00%0.0%
Q4 2016$761,000
+36.6%
120,220
-4.8%
0.00%
Q3 2016$557,000
+44.3%
126,220
-7.2%
0.00%
Q2 2016$386,000
+15.2%
136,020
+14.9%
0.00%
Q1 2016$335,000
-72.7%
118,420
-0.4%
0.00%
-100.0%
Q4 2015$1,228,000
-9.0%
118,950
+0.4%
0.00%0.0%
Q3 2015$1,350,000
-23.8%
118,420
-0.2%
0.00%0.0%
Q2 2015$1,771,000
+82.0%
118,600
+10.0%
0.00%0.0%
Q1 2015$973,000
-25.8%
107,8000.0%0.00%0.0%
Q4 2014$1,311,000
+24.4%
107,8000.0%0.00%0.0%
Q3 2014$1,054,000
-21.9%
107,800
+1.9%
0.00%0.0%
Q2 2014$1,349,000
+9535.7%
105,800
+1058.1%
0.00%
Q2 2013$14,0009,1360.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2018
NameSharesValueWeighting ↓
VHCP Management II, LLC 4,689,435$13,271,0008.73%
RTW INVESTMENTS, LP 1,973,932$5,586,0002.03%
VHCP Management, LLC 562,943$1,593,0001.38%
RA Capital Management 2,989,795$8,461,0001.08%
TANG CAPITAL MANAGEMENT LLC 430,000$1,217,0000.55%
Cormorant Asset Management, LP 1,080,000$3,056,0000.46%
Baker Brothers Advisors 15,010,534$42,480,0000.45%
DAFNA Capital Management LLC 149,642$423,0000.36%
GLOBEFLEX CAPITAL L P 413,941$1,171,0000.31%
CORRADO ADVISORS, LLC 119,125$337,0000.22%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders